Section Arrow
GLPG.NASDAQ
- Galapagos NV
Quotes are at least 15-min delayed:2026/04/09 04:22 EDT
Pre Market
Last
 28.22
-0.67 (-2.32%)
Bid
28.18
Ask
28.28
High 28.22 
Low 28.22 
Volume 300 
Regular Hours (Closed)
Last
 28.89
-0.04 (-0.14%)
Day High 
29.44 
Prev. Close
28.93 
1-M High
33.78 
Volume 
92.74K 
Bid
28.18
Ask
28.28
Day Low
28.5 
Open
29.4 
1-M Low
28.27 
Market Cap 
1.91B 
Currency 美元 
P/E 5.15 
%Yield -- 
10-SMA 29.57 
20-SMA 30.99 
50-SMA 32.72 
52-W High 37.78 
52-W Low 23.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.87/0.24
Enterprise Value
1.91B
Balance Sheet
Book Value Per Share
56.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.11B
Operating Revenue Per Share
8.74
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1831+0.0201+12.33%-- 
Pre Market 0.1857 +0.0026 +1.42%
VRAXVirax Biolabs Group Limited0.15+0.01+7.14%-- 
Pre Market 0.1477 -0.0023 -1.53%
ELABPmgc Holdings Inc4.5+1.05+30.43%0PE
Pre Market 4.3 -0.2 -4.44%
CUECue Biopharma0.2738+0.0856+45.48%-- 
Pre Market 0.2203 -0.0535 -19.54%
GERNGeron Corp1.71-0.03-1.72%-- 
Pre Market 1.7 -0.01 -0.58%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.